3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Urinary Bladder Neoplasms
2
Carcinoma, Transitional Cell
2
Urologic Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Lung Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Carboplatin
341
Paclitaxel
262
Cisplatin
233
Pemetrexed
226
Docetaxel
206
Erlotinib Hydrochloride
193
Gemcitabine
178
pembrolizumab
137
Bevacizumab
121
Radiotherapy
118
Nivolumab
84
Gefitinib
73
Vinorelbine
64
Cetuximab
58
atezolizumab
47
Afatinib
46
durvalumab
44
osimertinib
41
Radiosurgery
35
Ipilimumab
34
Drug Therapy
32
Taxes
30
Albumin-Bound Paclitaxel
29
130-nm albumin-bound paclitaxel
29
Surgical Procedures, Operative
28
Etoposide
25
Irinotecan
24
Sorafenib
21
Cyclophosphamide
20
Radiation
19
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Carcinoma, Non-Small-Cell Lung
×
apatorsen
×
Clear all
NCT01829113
2018-06-08
Spruce
SCRI Development Innovations, LLC
Phase 2
Completed
155 enrolled
12 charts